Government Halts Chelation Heart Disease Study
Government officials have stopped enrolling people in the largest alternative medicine study ever attempted as they investigate whether participants were fully informed of the risks and are being adequately protected.
Over 1,500 heart attack survivors are involved in the research, which tests a controversial treatment called chelation””mainly used to treat lead poisoning.
Dr. Gervasio Lamas of the University of Miami, who is leading the study, said more than two people have died, although the deaths were not a direct result of the treatments. He said he doesn’t know exactly how many deaths have occurred.
Some doctors who had been involved in the study have been disciplined by state boards or have criminal records and have been asked to drop out, he said.
“We think we have a safe and ethical trial and we’re protecting our patients,” said Lamas.
On Thursday, federal officials confirmed their probe of the $30 million study. Those directing the research, conducted at 100 sites around the United States and Canada, voluntarily stopped enrolling patients earlier this month, after the investigation was launched.
The study tested very high doses of vitamin and mineral supplements and chelation, which has not been proved effective for heart disease. Chelation (pronounced kee-LAY-shun) involves intravenous doses of a drug, in this case disodium EDTA, that proponents claim will bind to calcium built up in artery walls and help flush it from the body.
Medicines, surgery and artery-clearing angioplasty are the conventional treatments for heart disease.
Federal officials said many heart patients were exploring chelation therapy in 2002 when the study was approved, and the research would give answers about whether the treatment was safe and effective.
A separate effort looked to test chelation on autistic children. However, the government recently scrapped that plan, citing safety concerns as one reason.
Dr. Kimball Atwood, an anesthesiologist in suburban Boston and an assistant clinical professor at Tufts University, said the heart disease study was based on misrepresentations about safety and effectiveness and should never have been approved.
He and several others sent a complaint about the heart study to the federal research protection agency, and recently published a lengthy report detailing alleged problems.
“The consent form is inadequate. It doesn’t tell people, for example, that people have died from this drug,” said a report co-author, Liz Woeckner, president of Citizens for Responsible Care and Research, or CIRCARE, a nonprofit group focused on research safety.
Critics say there’s a conflict of interest as more than half of the doctors running the study make money by selling chelation treatments. Study documents misrepresent what previous, smaller chelation studies have found and “omit abundant evidence of injuries and deaths,” Atwood wrote.
Woeckner and Atwood’s article alleges problems with the licenses of several doctors who had roles in the trial, including a couple with criminal records.
“That’s frightening to me as a potential subject in the study,” Woeckner said.
A spokeswoman, Pat El-Hinnawy, said the federal Office for Human Research Protections determined there was merit to the complaint and opened an investigation.
Lamas had been at Mount Sinai Medical Center and the Miami Heart Institute in Miami Beach, Fla until June when he joined the University of Miami’s Miller School of Medicine.
The study’s leaders decided to stop enrolling subjects after the federal agency opened the probe. People already enrolled are still being treated, said a spokeswoman for the National Heart, Lung and Blood Institute, which is sponsoring the study with the National Center for Complementary and Alternative Medicine.
The American College for Advancement in Medicine, a group of chelation practitioners who helped design and run the research, said they vowed to work with Lamas “to answer the unfounded allegations of impropriety” and said federal officials “will find that the allegations are of a political nature.”
Dr. Jeanne Drisko said in a statement: “We call for a swift end to the moratorium and resumption of the trial,” says the statement by the group’s president.”
“Any study involving older heart attack survivors was bound to have deaths,” Lamas said. After federal officials questioned one death that study investigators had deemed unrelated to the trial, a change was made to report all deaths to the federal Food and Drug Administration, he said.
Lamas said many independent groups, including heart specialists at Duke University, are monitoring the study. “The last time they looked at this was at the end of April and there were no safety concerns,” he said.
The study, as originally designed in 2002, was to enroll nearly 2,400 people, 50 or older, who had suffered a heart attack at least six weeks previously. Some would be randomly assigned to get either chelation or dummy infusions weekly for 30 weeks, then 10 more treatments bimonthly, over a 28-month period. The assumption was that chelation would cut heart-related problems and deaths by one-fourth.
The study was set for others to be randomly assigned to get high or low doses of antioxidant vitamin and mineral supplements. The study was to have been nearly completed by now, but enrollment lagged and researchers now aim to sign up fewer than 2,000.
The American Heart Association and other groups have spoken out against chelation, as it has been highly controversial it. The heart group’s Web site says a single treatment costs $50 to $100. In the first month, patients usually are given daily treatments, which insurers do not cover since it is of unproven benefit.
A Dutch company, AkzoNobel, supplies the form of EDTA used in the trial, Lamas said.
“EDTA isn’t totally safe as a drug. There’s a real danger of kidney failure,” bone marrow problems, shock, low blood pressure, convulsions, heart rhythm problems, allergic reactions and breathing troubles, the heart association site says.
“A number of deaths in the United States have been linked with chelation therapy. Also, some people are on dialysis because of kidney failure caused, at least in part, by chelation therapy,” the site says. “Clearly, people who choose chelation therapy are risking more than money.”
The FDA, the American College of Physicians, the American Medical Association and others classify chelation as experimental and of unknown value or risk for heart disease patients.
Lamas said the controversy highlights the need to do a trial of this treatment. “It goes on all the time in many physicians’ offices in the U.S. and worldwide.”
Study documents list the American College of Cardiology as one of the groups associated with the research. The group’s president, Dr. W. Douglas Weaver, noted the treatment is “experimental, unproven.” But he supports finding out if it might work, and the Henry Ford Health System in Detroit where he works is participating.
“It would be a real disservice to scare people” and cause any study participants to stop treatments, because then we’d never have answers, Weaver said Thursday. If there were a safety concern, the federal government would have stopped the trial, rather than study leaders just suspending enrollment in it, he said.
On The Net: